Things may not have played out to plan for Biocon, Ltd.’s partnered biosimilar rival to NovoLog (insulin aspart), but the Indian firm is hopeful that a US approval should be in place towards the end of 2022.
While a response to the US Food and Drug Administration (FDA) complete response letter for the Viatris Inc.-partnered biosimilar...